This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Kiji Therapeutics


Kiji Therapeutics develops state-of-the-art off-the-shelf engineered cell therapies for multiple life-threatening diseases. Incorporated in France and Spain in 2023 with an initial seed from AdBio Partners. Kiji Tx has international Scientific Founders, Management and Scientific/Clinical Advisory Board, experienced in C&GT and product clinical development. With access to R&D and GMP manufacturing facilities in Madrid and Navara, Spain, Kiji Tx has operational readiness to develop the cell engineered platform and move to the clinic with its lead product, with a first patient expected in 2024. The company’s vision is to gene engineer iPSC-derived MSC cells for a targeted and optimized therapeutic benefit in a broad set of disease areas.